Chemomab Therapeutics to Report Third Quarter 2022 Financial Results and Provide a Business Update
11/01/2022 - 07:00 AM
TEL AVIV, Israel Nov. 1, 2022 Chemomab Therapeutics Ltd . (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced the company will release its third quarter 2022 financial results and provide a business update on Friday, November 11, 2022 at 8:00 am Eastern Time .
During the event, Chemomab's management team will review third quarter 2022 performance, discuss recent and upcoming developments and conduct a live question-and-answer session.
A replay of the call will be available on Chemomab's website for 90 days at www.chemomab.com .
Live Webcast and Conference Call at 8:00 am Eastern Time , Friday, November 11, 2022
Click this Webcast link to access the live webcast or replay.
The live webcast and replay can also be accessed at the News & Events section of the Investors page on the Chemomab website at investors.chemomab.com/events .
Conference Call Access via Telephone
US Investors: +1 (877) 407-9208
Please call 5-10 minutes before the scheduled start time, enter the conference passcode and ask the operator for the Chemomab conference call.
About Chemomab Therapeutics
Chemomab is a clinical stage biotechnology company focusing on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need. Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to bind and block CCL24 activity. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is currently in Phase 2 trials for primary sclerosing cholangitis and liver fibrosis, with a Phase 2 trial in systemic sclerosis expected to open around year-end, with first patients enrolled in early 2023. For more information, visit chemomab.com .
Contacts:
Investor Relations:
Media:
Irina Koffler
Barbara Lindheim
LifeSci Advisors, LLC
Chemomab Therapeutics
Phone: +1 (917) 734-7387
Consulting Vice President
ir@chemomab.com
Investor & Public Relations,
Strategic Communications
Phone: +1 (917) 355-9234
barbara@chemomab.com
https://www.prnewswire.com/news-releases/chemomab-therapeutics-to-report-third-quarter-2022-financial-results-and-provide-a-business-update-301664205.html
SOURCE Chemomab Therapeutics, Ltd.
Chemomab Therapeutics Ltd
CMMB Rankings
N/A Ranked by Stock Gains
CMMB Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
About CMMB
chemomab ltd. is a clinical-stage biotech company, focusing on discovery and development of innovative therapeutics for fibrosis-related diseases with large unmet need. chemomab is making great strides with its novel cm-101 proprietary platform, which hinders the fundamental function of the soluble chemokine ccl24 as a regulator of major inflammatory and fibrotic pathways in multiple fibrosis-related disorders. cm-101, the company’s lead clinical candidate, is a first-in-class monoclonal antibody that targets ccl24. chemomab has shown that cm-101 interferes with the underlying biology of fibrosis using a novel and differentiated mechanism of action. chemomab is actively advancing cm-101 into phase 2 studies to treat patients with liver fibrosis (primary sclerosing cholangitis and non-alcoholic steatohepatitis) and patients suffering from skin and lung fibrosis (systemic sclerosis).
